DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pemigatinib
Pemigatinib
Leukemia Insights June 2021
Incyte Announces the European Commission Approval of Pemazyre
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
Rxoutlook® 1St Quarter 2019
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors Francesco Facchinetti1, Antoine Hollebecque2, Rastislav Bahleda2, Yohann Loriot3, Ken A
Pemazyre – Criteria (PDF)
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Strengthening the Accelerated Approval Pathway: an Analysis of Potential Policy Reforms and Their Impact on Uncertainty, Access, Innovation, and Costs
Horizon Scanning Status Report December 2020
Pemigatinib (Pemazyre™) EOCCO POLICY
PCORI High Potential Disruption Report, November 2020
Oncology Approvals in 2020: a Year of Firsts in the Midst of a Pandemic
Oncology Oral, Other Therapeutic Class Review
Potential Exploration of Recent FDA-Approved Anticancer Drugs Against Models of SARS-Cov-2’S Main Protease and Spike Glycoprotein: a Computational Study
The Immune Microenvironment and Progression of Immunotherapy and Combination Therapeutic Strategies for Hepatocellular Carcinoma
Pemazyre, INN-Pemigatinib
Top View
Unraveling the Role of Fibroblasts, FGF5 and FGFR2 in HER2- Targeted Therapies Resistance and Tumor Progression
Informing Treatment Strategies Through a Comprehensive Approach
Therapeutic Advances in Oncology
Specialty Pipeline MONTHLY UPDATE
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity Against FGFR-Deregulated Tumors
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors Francesco Facchinetti1, Antoine Hollebecque2, Rastislav Bahleda2, Yohann Loriot3, Ken A
TAG Mail – 25 June 2020
Personalized Medicine at Fda
Pemazyre™ (Pemigatinib) (Oral) Document Number: IC-0534 Last Review Date: 05/01/2020 Date of Origin: 05/01/2020 Dates Reviewed: 05/2020
Molecular Pathways and Targeted Therapy in Cholangiocarcinoma
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Virtual Molecular Tumor Board: Recognition and Management of Targetable Tumor Mutations in Less Common Cancer Types
Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19–FGFR4–KLB Pathway Inhibition Vivek Subbiah 1 and Sumanta K
Oncology Medications Policy (1403)
Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
Drug Information Center Highlights of FDA Activities – 4/1/2020
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
Oncology Agents Policy #: Rx.01.67
CHMP Agenda of the 25-29 January 2021 Meeting
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Incyte Announces Positive CHMP Opinion for Pemigatinib for The
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
Mutational Landscape in Myeloproliferative Neoplasms (MPN) and Eosinophilia: Diagnostic and Treatment – Section 12
List Item Applications for New Human
FGFR Fusions in Cancer: from Diagnostic Approaches to Therapeutic Intervention
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Pipeline Report Report
New Prescription and OTC Medication Update
Foundationone®Cdx Technical Information
The Role of Fibroblast Growth Factor Receptor (FGFR)
Generic (Brand) Name Mechanism of Action Mechanism of Action
Pipeline Report
Download Overview
Touchoncology Touchexpert
409 Oncology Drugs
Precision Oncology Drug Approvals in 2020 - New Drugs and Expanded Indications
Targeted Therapy in Esophageal Cancer
Oncodeep® Is the Most Comprehensive Biomarker Test Designed to Help Oncologists Determine the Best Treatment(S) for Their Patients Living with Advanced Solid Tumors
Multi-Discipline Review
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Comprehensive Functional Evaluation of Variants of Fibroblast Growth Factor
Multifocal Serous Retinopathy with Pemigatinib Therapy for Metastatic Colon Adenocarcinoma Oleg Alekseev* , Efy Ojuok and Scott Cousins
Highlights in Digestive Oncology
Second-Line Treatment in Advanced Biliary Tract Cancer
Tyrosine Kinase Receptors in Oncology